Business Wire

Smiths Medical and Ivenix Partner to Revolutionize Infusion Management with First-Ever Comprehensive Suite of Infusion Solutions in US Healthcare Market

Share

Smiths Medical, a global medical device leader, today announced it has formed an exclusive partnership with Ivenix, Inc. that positions the companies as the first in the U.S. to offer a comprehensive suite of infusion management solutions to meet healthcare needs across the continuum of care. The long-term partnership, which includes a strategic investment from Smiths Medical, unites two innovators under a common goal of revolutionizing infusion management to improve patient safety and meet the needs of healthcare providers today and into the future.

Ivenix, a medical technology company dedicated to eliminating infusion-related patient harm, developed the first and only large-volume infusion pump from the ground up to meet the latest U.S. Food and Drug Administration infusion pump guidelines addressing recurring safety issues with pumps. Ensuring patient safety and clinical efficiency are critical components of successful life-saving infusion management. Today, infusion-related errors account for more than 50% of the 1.5 million adverse drug events reported annually to the FDA,1 and infusion-related adverse drug events cost the healthcare system more than $2 billion annually.2

Smiths Medical’s complementary portfolio of market-leading infusion systems CADD®-Solis and Medfusion® include syringe and ambulatory pumps that serve adult and neonatal critical care, operating rooms, and pain management in both the hospital and home. By adding the Ivenix Infusion System to its U.S. product portfolio, Smiths Medical will accelerate its offering into the large-volume infusion device segment, which is estimated to be over $2 billion.

“As a researcher focused on large volume IV smart pumps, I am well aware of the many safety and usability issues that exist with current products,” said Karen K. Giuliano, Ph.D., RN, FAAN, MBA, an Associate Professor and Co-director of the Nursing-Engineering Center for Innovation at the University of Massachusetts Amherst. “Innovation in IV smart pumps is long overdue, and I am happy to see new options for acute care clinicians to consider for the delivery of life-saving fluids and medications in this very important area of patient safety.”

“The long-term partnership between Smiths Medical and Ivenix will ensure that we are bringing the next generation of infusion management solutions to hospitals across the U.S. and fulfills our commitment to helping connect patients to life-saving therapies and insights to providers,” said JehanZeb Noor, Smiths Medical CEO. “Our investment in Ivenix will help spur the research and development needed to continue building on this critical resource and provide holistic solutions for hospitals and health systems.”

The Ivenix Infusion System includes a large-volume infusion pump with administration sets, infusion management tools and analytics to inform care and advance efficiency. The system received 510(k) clearance in 2019 and sets a new standard in infusion delivery by rethinking safety, simplicity, and interoperability. The system is centered around both the patient and clinician and designed to reduce infusion-related errors and drive down the total cost of ownership.

“This partnership allows us to accelerate the commercial reach of our infusion platform, and together provide a portfolio of leading-edge infusion solutions to deliver the highest standard of safe and integrated infusion care,” said Ivenix CEO Jorgen B. Hansen.

Smiths Medical will launch the Ivenix infusion System as part of its infusion portfolio in the summer of 2021.

About Smiths Medical

A leading innovator of specialized medical technologies for global markets, focusing on the medication delivery, vital care, and safety devices market segments. For more information, visit www.smiths-medical.com.

About Ivenix

Ivenix, Inc. is a medical technology company with a vision to eliminate infusion-related patient harm. The company was founded to develop innovative solutions that transform infusion delivery. Ivenix designed an infusion system from the ground up to streamline medication delivery and bring infusion technology into the digital age. The Ivenix Infusion System includes a large-volume infusion pump supported by a robust infusion management system designed to set new standards in simplicity, intelligence, and reliability. For more information, visit ivenix.com. The Ivenix Infusion System is cleared by the FDA.

References:

  1. FDA report, data on file
  2. ODPHP. Health Care Quality and Patient Safety: Adverse Drug Events. 2017

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

For Smiths Medical:
Bob Josephson
Robert.Josephson@fticonsulting.com
203-914-2372

For Ivenix:
Caroline Curran
caroline.curran@metiscomm.com
910-409-4126

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NameExperts.com Announces the Exclusive Category-Defining Website Watches.com for Acquisition13.5.2021 17:30:00 CEST | Press release

Name Experts LLC., a boutique domain name and website brokerage firm, announces the exclusive offering of Watches.com. Watches.com is a complete turn-key Website offering an Ecommerce end-to-end shopping experience with a lucrative B-to-C model. Watches.com has a significant organic profile, generating substantial traffic and revenues with a history of stable organic traffic. Watches.com currently ranks in position # 1 for the term “Watches” on Google. According to Domain expert Joe Uddeme, “Watches.com represents an opportunity to capitalize on the scale available with such a globally positioned category-defining URL. This is the pinnacle of beachfront real estate.” A unique opportunity exists to scale the property with additional lines of mainstream Watch brands and leveraging, additional industry-wide relationships. Watches.com is the singular source for unusual modern watches from around the world. Terms of Sale: Website Acquisition to include all content, intellectual property, so

Lunaphore Announces Appointment of Matthias Weber, Former President of Leica Biosystems, to Board of Directors13.5.2021 17:00:00 CEST | Press release

Lunaphore Technologies SA, a Swiss life-sciences company developing innovative next-generation equipment for cancer research, announces the appointment of Matthias Weber, former President of Leica Biosystems, to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005627/en/ Matthias Weber - The new member of Lunaphore’s Board of Directors (Photo: Business Wire) Mr. Weber brings extensive experience in the cancer diagnostics and immunohistochemistry fields, marked by excellence in a range of diverse strategic roles including Product Management, R&D, Operations, Sales & Marketing, and most notably as President at Leica Biosystems, a position which he held between 2012 and 2019. Mr. Weber commented: “I am delighted to join Lunaphore’s Board and to be part of a great team of innovators that will change the future of Immunohistochemistry (IHC) and Cancer Diagnostics”, and he added: “especially in the fiel

SentinelOne Receives Highest Score for Type B Use Case in the Gartner 2021 Critical Capabilities for Endpoint Protection Platforms13.5.2021 16:00:00 CEST | Press release

SentinelOne, the autonomous cybersecurity platform company, today announced that Gartner has positioned SentinelOne with the highest score in use case Type B in Gartner’s 2021 Critical Capabilities for Endpoint Protection Platforms report1. SentinelOne received the highest score for all three customer types out of 19 vendors. Gartner says, “Type B organizations aim to stay relatively current on technology without getting too far ahead or behind their competition.” “We believe receiving the highest product score among organizations prioritizing overall value in the 2021 Critical Capabilities for Endpoint Protection Platforms validates our vision and execution in delivering an AI-powered platform purpose built for the demands of the mainstream enterprise market,” said Raj Rajamani, Chief Product Officer, SentinelOne. “These organizations represent the largest market segment out of Gartner’s use cases and prioritize technology deployments that improve their organization’s productivity, pr

Wipro Has Earned the Microsoft Windows Virtual Desktop Advanced Specialization13.5.2021 15:12:00 CEST | Press release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today said it has earned the Microsoft Windows Virtual Desktop advanced specialization, a validation of a partner’s deep knowledge, extensive experience and expertise in deploying, scaling and securing virtual desktop infrastructure on Azure. Only partners that meet stringent criteria around customer success and staff skilling, as well as pass a third-party audit of their Windows Virtual Desktop technical practices are able to earn the Microsoft Windows Virtual Desktop advanced specialization. Supporting secure remote work for employees is more critical than ever. Windows Virtual Desktop is a Microsoft solution that seamlessly integrates with other Microsoft products and allows customers to implement virtual desktops in a scalable, secure, and cost-effective way. Partners with validated capabilities in implementing Windows Virtual Desktop can he

Schlumberger Appoints Dr. Katharina Beumelburg as Chief Strategy and Sustainability Officer13.5.2021 15:00:00 CEST | Press release

Schlumberger announced today the appointment of Dr. Katharina Beumelburg to the position of Chief Strategy and Sustainability Officer, Schlumberger Limited, reporting to Olivier Le Peuch, Chief Executive Officer. The appointment is effective Monday, May 17. As a member of the executive team, Dr. Beumelburg will oversee corporate strategy, sustainability, marketing and communications activities across the Company. Dr. Beumelburg joins Schlumberger from a global technology company, Siemens, where she has held various leadership positions including strategy development incorporating sustainability; management consulting; business excellence; and operations management. In her most recent position, she led the global Transmission Services business. “I am delighted to welcome Katharina to the Schlumberger team at a pivotal time for the company, the energy industry and our planet. Sustainability is increasingly core to our performance strategy, through which we will realize our vision,” said

Ferring and Rebiotix to Present Landmark Data for Investigational Microbiota-based Live Biotherapeutic RBX2660 at Digestive Disease Week ® (DDW) 202113.5.2021 14:00:00 CEST | Press release

Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced that Phase 3 data evaluating its investigational microbiota-based live biotherapeutic RBX2660 for reduction of recurrent Clostridioides difficile(C. difficile) infection will be presented as part of an invited talk at Digestive Disease Week® (DDW) 2021. The congress will take place virtually from May 21-23, 2021. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210513005129/en/ “These data are the pinnacle of a decade of ground-breaking research and development, driven by the goal of helping those who are experiencing the debilitating effects of recurrent C. difficile infection,” said Lee Jones, Founder, President and Chief Executive Officer of Rebiotix, a Ferring Company. “We’re striving to deliver innovative therapeutics to help people live better lives, and are proud to be pioneering a new category of scientifically-validated, microbiome-based therapeu

S&P Global Ratings Recognizes PMI’s Business Transformation as Industry Differentiator13.5.2021 13:59:00 CEST | Press release

Philip Morris International Inc. (PMI) (NYSE:PM) is transforming its business to deliver a smoke-free and sustainable future. Today, the company announced that S&P Global Ratings’ ESG Evaluation report has assessed PMI’s approach to environmental, social, and governance (ESG) topics and confirmed that PMI has positively differentiated itself within the tobacco sector. The S&P Global Ratings ESG evaluation assesses a company’s ESG strategy and ability to prepare for potential future risks and opportunities, and provides a forward-looking, long-term opinion of a company’s readiness for disruptive ESG risks and opportunities. It provides an overall score that allows comparison with other entities globally, including sector peers, and consists of a combined sector/region score, an entity-specific score, and a preparedness score. Based on entity-specific scores — designed to indicate how a company is actively and effectively managing its exposure to ESG risks and opportunities compared with